Gangagen

Bengaluru, India· Est. 2020

GangaGen engineers bacteriophage-derived endolysin proteins to create targeted, novel antibiotics for drug-resistant bacterial infections.

gangagen.com

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

Private Company

Funding information not available

AI Company Overview

GangaGen engineers bacteriophage-derived endolysin proteins to create targeted, novel antibiotics for drug-resistant bacterial infections.

Infectious Disease

Technology Platform

Platform for engineering bacteriophage-derived endolysin proteins into targeted, novel antimicrobial agents with novel mechanisms of action against drug-resistant bacteria.

Opportunities

Significant opportunity driven by the global antimicrobial resistance crisis, regulatory incentives for novel antibiotics (like LPAD), and potential for high unmet need pricing in a market with few novel entrants.

Risk Factors

High technical risk in translating engineered proteins into effective systemic therapeutics; clinical and regulatory pathway for novel enzybiotics is less defined than for small molecules; challenging commercial market for anti-infectives despite clinical need.

Competitive Landscape

Competes with other phage therapy companies (e.g., Adaptive Phage Therapeutics, Locus Biosciences) and novel antibiotic developers (e.g., Entasis, Spero). Differentiation lies in the engineered endolysin protein approach, offering potential advantages in specificity and manufacturability over whole phage therapies.

More companies in India →